AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT02998528 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: Specified dose on specified days
Study NCT02998528 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Paclitaxel
Description: Specified dose on specified days
Study NCT02998528 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Ipilimumab
Description: This arm is closed and no longer enrolling patients.
Study NCT04374136 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AL001
Description: Administered via intravenous (IV) infusion
Study NCT04374136 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administered via intravenous (IV) infusion
Study NCT01470495 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: RFA
Description: treat Recurrent HCC with RFA
Study NCT00470067 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: carboplatin
Description: IV
Study NCT00470067 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pegylated liposomal doxorubicin hydrochloride
Description: IV
Study NCT02576912 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Active Delta-9-THC
Description: Active Delta-9-THC (0.036 mg/kg) given intravenously.
Study NCT02576912 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Active Pregnenolone
Description: A dose given sublingually.
Study NCT02576912 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: A placebo dose given sublingually.
Study NCT02576912 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: A placebo dose given sublingually.
Study NCT02576912 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo dose given intravenously.
Study NCT02576912 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo dose given intravenously.
Study NCT03402750 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Meds to Beds
Description: Medications will be delivered to patient bedside before discharge
Study NCT03402750 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Electronic Prescription
Description: Patient or surrogate can pick up medication from pharmacy
Study NCT03735069 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: IPT (Indirect pulp treatment)
Description: Indirect pulp treatment involves complete caries excavation from the dentin-enamel junction using a round bur. Caries near the pulp is removed with caution using spoon excavator until the remaining dentine shows increased resistance to manual instrumentation. A layer of resin-modified glass ionomer (RMGI) dressing material is placed, followed by resin-modified glass ionomer (RMGI) build-up material, and the final restoration; a preformed Stainless Steel Crown (SSC).
Study NCT03735069 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Cvek/partial pulpotomy
Description: Cvek/partial pulpotomy involves removal of inflamed pulp tissue to depth until healthy pulp tissue is reached (depth of 2-4 mm), as indicated by healthy bleeding and arrest of hemorrhage upon pressure with a cotton pellet moistened with 2.5% NaOCl for 2-5 minutes and repeated for two times if required. Gray MTA will be placed in the pulp chamber in 2-3 mm thickness, moist cotton pellet will be placed to ensure setting and the tooth will be temporized with IRM, the patient will be reviewed after 1 week. If the tooth is asymptomatic, final restoration with RMGIC and stainless steel crown will be placed , and a post-operative radiograph will be taken.
Study NCT03735069 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Cervical pulpotomy
Description: Cervical pulpotomy involves removal of inflamed pulp tissue from all pulp chamber as indicated by healthy bleeding and arrest of hemorrhage upon pressure with a cotton pellet moistened with 2.5% NaOCl for 6 minutes and repeated for two times if required. Gray MTA will be placed in the pulp chamber (2-3mm) thickness, moist cotton pellet will be placed to ensure setting and the tooth will be temporized with IRM, the patient will be reviewed after 1 week. If the tooth is asymptomatic, final restoration with RMGIC and stainless steel crown will be placed , and a post-operative radiograph will be taken.
Study NCT00005983 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: radiation therapy
Study NCT00005983 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: surgery
Description: surgery
Study NCT00005983 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: surgery
Description: surgery
Study NCT04285593 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Bulgarian squats
Description: The intervention using Bulgarian squat exercises will consist in the application of the protocol described by Aguilera-Castells et al. The technique will be done with the footballer standing. The athlete with one foot in front and the other behind the body, arms crossed over her chest, and her upper body, will remain upright with a natural swing in the lower back during the entire exercise. The players will lower the body (eccentric phase) until the front knee flexes to 90º. Subsequently, they will return to the initial position with a full extension of the knee of the front leg (concentric phase), maintaining an erect trunk position. The front foot will be placed in a fixed position contacting the ground, and the rear foot will rest on a horizontal press bench.
Study NCT02293369 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Cuff closure via vaginal route
Description: Vaginal cuff will be closed via vaginal route during total laparoscopic hysterectomy.
Study NCT02293369 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Cuff closure via laparoscopic route
Description: Vaginal cuff will be closed via laparoscopic route during total laparoscopic hysterectomy.
Study NCT00460538 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Lectranal
Description: Dosage form: capsule~1: Dosage: 2 capsule Frequency and duration: 2 times daily over the 6 weeks
Study NCT00460538 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Dosage form: capsule 2: Dosage: 2 capsules Frequency and duration: 2 times daily over the 6 weeks
Study NCT01104779 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cariprazine
Description: Patients who meet eligibility criteria will be administered a once daily oral dose of cariprazine for six weeks. Upon completion of the study or early termination, patients will undergo a two week safety follow-up period.
Study NCT01104779 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Patients who meet eligibility criteria will be administered a once daily oral dose of placebo for six weeks. Upon completion of the study or early termination, patients will undergo a two week safety follow-up period.
Study NCT02006693 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: XEN® Gel Stent
Description: The XEN® Gel Stent (XEN45 implant) was placed in the study eye.
Study NCT02006693 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Cataract Surgery
Description: Participants diagnosed with a cataract elected to have cataract surgery.
Study NCT01589965 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Financial incentive through lotteries
Description: Introduction of financial incentives in the form of a lottery to remain/become STI-negative, which we believe is both replicable and relatively easy to scale-up.
Study NCT02125253 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mometasone Furoate Nasal Spray, 50 mcg
Description: a metered-dose, manual pump spray unit containing an aqueous suspension of mometasone furoate
Study NCT02125253 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nasonex Nasal Spray, 50 mcg
Description: a metered-dose, manual pump spray unit containing an aqueous suspension of mometasone furoate monohydrate
Study NCT02125253 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Nasal Spray
Description: a metered-dose, manual pump spray unit containing an aqueous suspension
Study NCT04668911 — intervention group
Intervention type: OTHER
Intervention: Swab
Description: PCR test for SARS-CoV2, oral and nasal swab
Study NCT02504671 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK3196165
Description: GSK3196165 is supplied as liquid and will be administered as SC injection.
Study NCT02504671 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MTX
Description: MTX will be supplied as capsule, tablet or liquid and will be administered orally or as SC injection.
Study NCT04374136 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Open label - AL001
Description: Administered via intravenous (IV) infusion
Study NCT02504671 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: MTX
Description: MTX will be supplied as capsule, tablet or liquid and will be administered orally or as SC injection.
Study NCT02504671 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Folic acid
Description: Folic acid will be supplied as capsule, tablet or liquid and will be administered orally.
Study NCT02504671 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Folic acid
Description: Folic acid will be supplied as capsule, tablet or liquid and will be administered orally.
Study NCT02504671 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo is supplied as liquid as sterile 0.9% weight by volume (w/v) sodium chloride solution and will be administered as SC injection
Study NCT04102280 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Dialyser
Description: Three consecutive treatment weeks and one follow-up week per patient. Each treatment week includes three hemodiafiltration HDF sessions and is assigned to one type of dialyzer: FX P600 Fresenius Medical Care, comparator Xevonta Hi 15 (B. Braun) and comparator Elisio 150H (Nipro)
Study NCT04300283 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Hypnosis
Description: See previous description
Study NCT02183207 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Percutaneous Endoscopic Gastrostomy
Description: Percutaneous Endoscopic Gastrostomy by introducer method via visualization through E.G. ScanTM
Study NCT02315196 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pegylated liposomal doxorubicin hydrochloride
Description: Given IV
Study NCT02002065 — intervention group
Intervention type: BIOLOGICAL
Intervention: Inactivated HAV vaccine
Description: Inactivated vaccine: 0.5 ml per dose containing 250 u antigen, one dose
Study NCT02002065 — intervention group
Intervention type: BIOLOGICAL
Intervention: Attenuated alive HAV vaccine
Description: Attenuated alive vaccine: 1.0 ml per dose containing 6.50 lgCCID50 alive virus, one dose
Study NCT02315196 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: epirubicin hydrochloride
Description: Given IV
Study NCT02315196 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: carboplatin
Description: Given IV
Study NCT03491904 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fasinumab AI
Description: Self-administered with auto injector
Study NCT02315196 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: therapeutic conventional surgery
Description: Undergo definitive surgery
Study NCT02315196 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: paclitaxel
Description: Given IV
Study NCT03491904 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fasinumab PFS
Description: Prefilled syringe administered by study staff
Study NCT02315196 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies
Study NCT02315196 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: quality-of-life assessment
Description: Ancillary studies
Study NCT00616772 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABT-335
Description: Capsule
Study NCT00616772 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Capsule
Study NCT00616772 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Atorvastatin
Description: Capsule
Study NCT00616772 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Atorvastatin
Description: Capsule
Study NCT02295436 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: minodronic acid
Description: comparison of different doses, ages and medication conditions
Study NCT01695213 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: uncemented total hip arthroplasty
Study NCT01782404 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Chlorhexidine
Description: Bladder irrigation with chlorhexidine 0.2 mg/ml twice daily
Study NCT05840523 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Proprioceptive Neuromuscular Facilitation exercises
Description: The PNF group performed flexion-abduction-internal rotation and extension-abduction-internal rotation patterns as 15 repetitions, 2 sets. The metronome was used to fix the construction speed of the exercises (50bpm). PNF exercises were performed with EB at a metronome speed of 50bpm at a ratio of 1:2 sec. In other words, while transition from the antagonist to agonist pattern in 3 clicks, there was return from agonist to antagonist in 6 clicks.
Study NCT02909686 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Boswellia Serrata
Study NCT02909686 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Curcumin
Study NCT05840523 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: The Range Of Motion exercises
Description: The ROM group performed hip flexion abduction, neutral abduction and extension abduction exercises with an EB at 50bpm metronome speed in 3 sets of 10 repetitions. In both groups, 30 seconds of rest was given between exercises.
Study NCT03862755 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chemoprophylaxis with Low Molecular Weight Heparin (LMWH)
Description: Early chemoprophylaxis means low-molecular weight heparin (LMWH) 3075 IU (WHO Units) injection subcutaneously one time a day no later than 24 hours after surgery. Early ambulation means activity out of bed no later than 24 hours after surgery. According to different risk level, patients received different thromboprophylaxis strategies. Early ambulation alone was for patients at low risk (Caprini 0-4), early chemoprophylaxis plus early ambulation was for patients at moderate (Caprini 5-8) or high risk (Caprini ≥9).
Study NCT02887456 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Endodontic treatment using Vitapex
Description: Endodontic treatment using Vitapex
Study NCT02887456 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Endodontic treatment using MTA paste
Description: Endodontic treatment using MTA paste
Study NCT01996618 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ranolazine
Description: After the initial 6 days of treatment with ranolazine, 500 mg twice daily or matched placebo, subjects will undergo repeat 24 hour electrocardiographic monitoring. If tolerated, the subjects will then have their study medication increased (Ranolazine 1,000 mg twice daily) with the plan to then undergo a repeat 24 hour ambulatory electrocardiographic monitoring in 6 days.
Study NCT02373189 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Bright light
Description: The purpose of this R34 Pilot and Feasibility study is to develop a morning bright light treatment to help manage chronic pain and improve PTSD symptoms, mood, and sleep in US veterans. Veterans will have 7 baseline days at home, followed by a baseline pain sensitivity assessment and baseline home circadian phase assessment (dim light melatonin onset). Following an instructional home visit, patients will then self-administer morning bright light treatment for 6 days, followed by reassessments of pain sensitivity and home circadian phase. This will be repeated after a further 7 days of morning bright light treatment. The Patient Reported Outcomes Measurement Information System (PROMIS) will also be administered at every lab visit. Additionally, pain and mood (electronic diaries) and sleep (wrist actigraphy) will be assessed daily throughout baseline and treatment. Pain, mood and sleep will also be self-reported daily during a 1 month follow up after cessation of light treatment.
Study NCT02084602 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Artesunate
Description: Orally administration of artesunate 4mg/Kg by three days
Study NCT00369278 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Enteric-coated mycophenolate sodium (EC-MPS)
Description: Tablets for oral administration
Study NCT00369278 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Enteric-coated mycophenolate sodium (EC-MPS)
Description: Tablets for oral administration
Study NCT03086148 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketamine
Description: Ketamine will be administrated intravenously at dural opening, with the total dose of 0.5 mg/kg and continual infusion for 40 minutes.
Study NCT03086148 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Normal saline
Description: Normal saline will be administrated intravenously at dural opening, with the total dose of 0.5 ml/kg and continual infusion for 40 minutes.
Study NCT00446797 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Non-selective NSAIDS
Description: Non-selective NSAIDs administered at usual (standard) doses.
Study NCT00446797 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Celecoxib
Description: celecoxib with an initial loading dose of 400 mg followed by 200 mg twice daily (BID) for up to 7 days.
Study NCT02084602 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mefloquine
Description: Orally administration of mefloquine 15mg/Kg in the fourth day Orally administration of mefloquine 10mg/Kg in the fifth day
Study NCT03547037 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-63723283
Description: JNJ-63723283 will be administered intravenously.
Study NCT03547037 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Erdafitinib
Description: Erdafitinib will be administered orally.
Study NCT03694327 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CT-101-M
Description: Mobile Application
Study NCT03694327 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: QuitGuide
Description: Mobile Application
Study NCT01160172 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Staphylococcal investigational vaccine GSK2392103A
Description: intramuscular vaccination according to protocol schedule
Study NCT01160172 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Staphylococcal investigational vaccine GSK2392105A
Description: intramuscular vaccination according to protocol schedule
Study NCT01160172 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Staphylococcal investigational vaccine GSK2392106A
Description: intramuscular vaccination according to protocol schedule
Study NCT01160172 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Staphylococcal investigational vaccine GSK2392019A
Description: intramuscular vaccination according to protocol schedule
Study NCT01160172 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Saline placebo
Description: intramuscular vaccination according to protocol schedule
Study NCT03808532 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cura+ Moisturizing Cream
Description: Parents of at-risk infants in the intervention arm will be instructed to apply moisturizer to the infant's entire body once daily for six months.
Study NCT03384212 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cladribine
Study NCT02909686 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Epimedium
Study NCT02909686 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Fisetin
Study NCT02909686 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Luteolin
Study NCT02909686 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Nettle
Study NCT02909686 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Pycnogenol
Study NCT02909686 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Reishi Mushroom
Study NCT02909686 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Resveratrol
Study NCT02909686 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT00398138 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: WT-1 analog peptide vaccine
Study NCT00398138 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: incomplete Freund's adjuvant
Study NCT00398138 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: sargramostim
Study NCT00398138 — intervention group
Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: polymerase chain reaction
Study NCT00398138 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: flow cytometry
Study NCT00398138 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: immunoenzyme technique